Zacks Research Predicts Amarin's Q1 Earnings (NASDAQ:AMRN)

Amarin Co. plc (NASDAQ:AMRN - Free Report) - Research analysts at Zacks Research issued their Q1 2027 earnings estimates for Amarin in a research report issued to clients and investors on Thursday, April 24th. Zacks Research analyst R. Department anticipates that the biopharmaceutical company will earn ($0.69) per share for the quarter. The consensus estimate for Amarin's current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin's FY2027 earnings at ($3.80) EPS.

Several other research firms have also recently commented on AMRN. The Goldman Sachs Group lowered their target price on shares of Amarin from $20.00 to $7.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. StockNews.com initiated coverage on Amarin in a research report on Wednesday, April 16th. They issued a "sell" rating for the company.

Amarin Stock Down 6.7 %

Amarin stock traded down $0.75 during mid-day trading on Friday, hitting $10.43. 55,645 shares of the company's stock traded hands, compared to its average volume of 73,953. The company has a market cap of $214.17 million, a PE ratio of -115.89 and a beta of 1.38. Amarin has a one year low of $7.08 and a one year high of $20.60. The firm has a 50 day moving average price of $9.62 and a 200 day moving average price of $10.37.

Amarin (NASDAQ:AMRN - Get Free Report) last announced its quarterly earnings results on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) EPS for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The firm had revenue of $62.31 million during the quarter, compared to analyst estimates of $32.37 million.

Hedge Funds Weigh In On Amarin

Large investors have recently made changes to their positions in the business. Arkfeld Wealth Strategies L.L.C. lifted its stake in Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 20,000 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Amarin in the 4th quarter worth $36,000. Generation Capital Management LLC acquired a new position in shares of Amarin in the 4th quarter worth $50,000. Stonepine Capital Management LLC purchased a new stake in shares of Amarin during the fourth quarter valued at $55,000. Finally, New York State Common Retirement Fund acquired a new position in shares of Amarin in the 4th quarter valued at $68,000. Institutional investors own 22.25% of the company's stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.